Katherine Ansley, MD
@KatherineAnsley
Followers
305
Following
3K
Media
88
Statuses
859
Med Onc specializing in breast cancer at Atrium Health Wake Forest Baptist. The views here are my own and do not necessarily reflect those of Advocate Health
Joined July 2009
RT @OncLive: Oral SERDs and PI3K Inhibitors Move the Needle Beyond CDK4/6 Inhibitors in Metastatic Breast Cancer.@KatherineAnsley @AtriumHe….
onclive.com
Katherine C. Ansley, MD, discusses the role of oral SERDs and PI3K and AKT inhibitors for the treatment of metastatic breast cancer.
0
1
0
RT @OncLive: We present the #FiveUnder5 🕘, your go-to roundup of the top 5️⃣ #oncology videos of the week. View the clips 📹: https://t.co/….
0
6
0
RT @PTarantinoMD: The curves everybody’s been waiting for. First line T-DXd + pertuzumab significantly prolonged PFS over THP for HER2+ M….
0
118
0
RT @DrSGraff: As anticipated, SERENA-6 creates a lot of questions. PFS-2 is immature and crossover was not allowed; given PFS on postMona….
0
25
0
RT @ErikaHamilton9: 3rd @NEJM publication for #bcsm at #ASCO25 in the last 2 days (that I'm aware of!). #camizestrant #ESR1 . Come to plen….
nejm.org
Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor plus a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor for advanced breast cancer....
0
19
0
RT @drsarahsam: First-line Sacituzumab + Pembrolizumab improves PFS in 1st Line TNBC. 🚨🔔‼️. Crossover 80% Sacituzumab Offered! . Very few p….
0
35
0
RT @LevineCancer: 🎉 Congratulations to Dr. Heidi Klepin for receiving the prestigious B.J. Kennedy Geriatric Oncology Award at #ASCO25! It….
0
4
0
RT @ErikaHamilton9: #ASCENT04 showing sacituzumab + pembro better for 1L PDL1+ TNBC than chemo + pembro. PFS: 7.8 vs. 11.2 mo, HR 0.65. OR….
0
8
0
RT @DrHBurstein: Data for the oral taxane, DHP107, were pretty compelling. Looks the 'same' as IV paclitaxel; met all non-inferiority crit….
0
15
0
Congratulations @HKlepinMD on the @ASCO Award for Geriatric Oncology! Master clinician, educator, scientist and just overall good human 🩷 @WakeCancer @AtriumHealthWFB
0
0
4
RT @drsarahsam: MINI Trial by Dr Sohn shows 30 month PFS is 1st Line ER+, HER2+ MBC with chemotherapy free regimen of tras, letrozole and r….
0
6
0
RT @drsarahsam: A first-line metastatic TNBC progression free survival beyond 1 year is very welcome for our patients and this was mostly P….
0
19
0
RT @VKaklamani: Great inavo OS data. The 2 year delay of chemo is impressive. But questioning the small subgroup of >65 and worsening OS. S….
0
6
0
RT @PTarantinoMD: The 19th St. Gallen Conference took place this week in Vienna. Nearly 80 expert panelists voted on key debated topics in….
0
169
0
0
1
0